Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.
about
Recent Advances in Lentiviral Vaccines for HIV-1 InfectionPros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesVirological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapyGeneration of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.The feasibility of incorporating Vpx into lentiviral gene therapy vectors.Design of a titering assay for lentiviral vectors utilizing direct extraction of DNA from transduced cells in microtiter plates.Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectorsHIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.Differences in vector-genome processing and illegitimate integration of non-integrating lentiviral vectorsVpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.
P2860
Q26742169-0A31B184-F866-4F5C-A70D-6BBE275F5A3AQ27013679-1F64A204-EE92-4322-9191-6D8D0E1F364EQ35069876-53B6F2B6-A396-4D06-A505-0618BFB91D6AQ35878409-5FB84C71-120C-4EBF-8D52-DFFDEE7869E0Q37225212-6C07F8C7-9DFE-4A85-A679-F8FC92A4440CQ37350713-2946111A-9D1C-449F-99E4-1944440068CAQ38530074-5D0BA447-C58C-4E3A-BF2E-24058B018D9BQ38869040-A1197E5C-EABA-4EB2-A2C0-62E58582D842Q40348395-F2ABFF30-ACB7-458A-9EE3-6D46ACEC3D1EQ40532525-A6C34EB0-FB02-43CB-B932-23097ED46145Q41347747-AED56FF0-A058-4170-8A39-4E470E881A99Q47244891-F1F00FCE-76CB-4490-83B2-DFB5C9F1F80A
P2860
Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design of a novel integration- ...... target human dendritic cells.
@en
Design of a novel integration- ...... target human dendritic cells.
@nl
type
label
Design of a novel integration- ...... target human dendritic cells.
@en
Design of a novel integration- ...... target human dendritic cells.
@nl
prefLabel
Design of a novel integration- ...... target human dendritic cells.
@en
Design of a novel integration- ...... target human dendritic cells.
@nl
P2093
P2860
P356
P1433
P1476
Design of a novel integration- ...... target human dendritic cells.
@en
P2093
Brenna Kelley-Clarke
Chintan D Vin
Christopher J Nicolai
Derek D Sloan
James M Allen
Jared M Odegard
Linda A Cassiano
Lisa T Nelson
Neal Van Hoeven
Scott H Robbins
P2860
P304
P356
10.1038/MT.2013.278
P577
2013-12-06T00:00:00Z